Giulia Glorani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giulia Glorani has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Sola-Leyva
Division of Obstetrics and Gynecology, Department of Clinical Science Intervention and Technology, Karolinska Institute Huddinge Stockholm Sweden
1 shared publication - Alessandro Romeo
LAPS ‐ Laboratory for Photovoltaics and Solid State Physics, Department of Computer Science University of Verona Verona Italy
1 shared publication - Concepcion Jimenez-Lopez
Department of Microbiology, University of Granada, 18071 Granada, Spain
1 shared publication - Federica Vurro
Department of Computer Science, University of Verona, 37134 Verona, Italy
1 shared publication - Guillermo Ramon Iglesias
NanoMag Lab, Department of Applied Physics, Faculty of Science, University of Granada, Edificio I+D Josefina Castro, Av. de Madrid, 28, 18012 Granada, Spain
1 shared publication - Laura Calderan
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona
1 shared publication
Latest Publications
- Open Access
- 18 March 2021
- Published by MDPI AG in Nanomaterials
- Vol. 11 (3) , 766
Improving the Cellular Uptake of Biomimetic Magnetic Nanoparticles
Magnetococcus marinus magnetosome-associated protein MamC, expressed as recombinant, has been proven to mediate the formation of novel biomimetic magnetic nanoparticles (BMNPs) that are successful drug nanocarriers for targeted chemotherapy and hyperthermia agents. These BMNPs present several advantages over inorganic magnetic nanoparticles, such as larger sizes that allow the former to have larger magnetic moment per particle, and an isoelectric point at acidic pH values, which allows both the stable functionalization of BMNPs at physiological pH value and the molecule release at acidic (tumor) environments, simply based on electrostatic interactions. However, difficulties for BMNPs cell internalization still hold back the efficiency of these nanoparticles as drug nanocarriers and hyperthermia agents. In the present study we explore the enhanced BMNPs internalization following upon their encapsulation by poly (lactic-co-glycolic) acid (PLGA), a Food and Drug Administration (FDA) approved molecule. Internalization is further optimized by the functionalization of the nanoformulation with the cell-penetrating TAT peptide (TATp). Our results evidence that cells treated with the nanoformulation [TAT-PLGA(BMNPs)] show up to 80% more iron internalized (after 72 h) compared to that of cells treated with BMNPs (40%), without any significant decrease in cell viability. This nanoformulation showing optimal internalization is further characterized. In particular, the present manuscript demonstrates that neither its magnetic properties nor its performance as a hyperthermia agent are significantly altered due to the encapsulation. In vitro experiments demonstrate that, following upon the application of an alternating magnetic field on U87MG cells treated with BMNPs and TAT-PLGA(BMNPs), the cytotoxic effect of BMNPs was not affected by the TAT-PLGA enveloping. Based on that, difficulties shown in previous studies related to poor cell uptake of BMNPs can be overcome by the novel nanoassembly described here.
- 18 March 2021
- Published by MDPI AG in Nanomaterials
- Vol. 11 (3) , 766
Open AccessImproving the Cellular Uptake of Biomimetic Magnetic Nanoparticles
Magnetococcus marinus magnetosome-associated protein MamC, expressed as recombinant, has been proven to mediate the formation of novel biomimetic magnetic nanoparticles (BMNPs) that are successful drug nanocarriers for targeted chemotherapy and hyperthermia agents. These BMNPs present several advantages over inorganic magnetic nanoparticles, such as larger sizes that allow the former to have larger magnetic moment per particle, and an isoelectric point at acidic pH values, which allows both the stable functionalization of BMNPs at physiological pH value and the molecule release at acidic (tumor) environments, simply based on electrostatic interactions. However, difficulties for BMNPs cell internalization still hold back the efficiency of these nanoparticles as drug nanocarriers and hyperthermia agents. In the present study we explore the enhanced BMNPs internalization following upon their encapsulation by poly (lactic-co-glycolic) acid (PLGA), a Food and Drug Administration (FDA) approved molecule. Internalization is further optimized by the functionalization of the nanoformulation with the cell-penetrating TAT peptide (TATp). Our results evidence that cells treated with the nanoformulation [TAT-PLGA(BMNPs)] show up to 80% more iron internalized (after 72 h) compared to that of cells treated with BMNPs (40%), without any significant decrease in cell viability. This nanoformulation showing optimal internalization is further characterized. In particular, the present manuscript demonstrates that neither its magnetic properties nor its performance as a hyperthermia agent are significantly altered due to the encapsulation. In vitro experiments demonstrate that, following upon the application of an alternating magnetic field on U87MG cells treated with BMNPs and TAT-PLGA(BMNPs), the cytotoxic effect of BMNPs was not affected by the TAT-PLGA enveloping. Based on that, difficulties shown in previous studies related to poor cell uptake of BMNPs can be overcome by the novel nanoassembly described here.